In the past century, few areas of biology advanced as much as our understanding of the pathways of intermediary metabolism. Initially considered unimportant in terms of gene regulation, crucial cellular fate changes, cell differentiation, or malignant transformation are now known to involve 'metabolic remodeling' with profound changes in the expression of many metabolic enzyme genes. This review focuses on the recent identification of RNA-binding activity of numerous metabolic enzymes. We discuss possible roles of this unexpected second activity in feedback gene regulation ('moonlighting') and/or in the control of enzymatic function. We also consider how metabolism-driven post-translational modifications could regulate enzyme-RNA interactions. Thus, RNA emerges as a new partner of metabolic enzymes with far-reaching possible consequences to be unraveled in the future.
The discovery of the nuclear hormone receptors (NHRs) in the 1980s represented a breakthrough in the understanding of the transcriptional control of metabolic networks. NHRs represent an extended family of ligand-responsive DNA-binding proteins that, upon activation, can switch transcriptional programs in cooperation with coactivators or corepressors [3] . NHRs are transcriptional master regulators of metabolism by altering the metabolic enzyme profiles in response to feeding and fasting as well as circadian signaling. An illustrative example is the role of NHRs in liver metabolism. Secretion of cortisol from the adrenal gland during prolonged starvation induces the activation of the glucocorticoid receptor in the liver. This leads to the transcription of two master regulators of sugar metabolism, glucose-6-phosphatase (G6PC) and phosphoenolpyruvate carboxykinase (PECK), which promote the synthesis of glucose via gluconeogenesis [1, 4] . By contrast, liver X receptors (LXRs) and farnesoid X receptor (FXR) are activated by feeding-induced synthesis of their respective ligands, oxysterols and bile acid. In antagonism to fasting-activated NHRs, both LXRs and FXR suppress gluconeogenesis by
Trends
Genetic control of metabolism is currently best understood at the level of transcription and epigenetics. Only limited information is available on post-transcriptional regulation of metabolism.
While a few metabolic enzymes were previously known to moonlight as RNA-binding proteins in physiologically relevant contexts, recent discoveries highlight that several dozen of metabolic enzymes belonging to a wide spectrum of pathways exhibit RNAbinding activity in living mammalian cells.
Abundant RNA-enzyme interactions might suggest novel roles of RNA in affecting enzyme function, for instance, as competitive inhibitors or allosteric regulators. A function of RNA as assembly scaffold for enzyme complexes is also conceivable, with potentially wide-ranging implications for our understanding of how cells organize and control metabolic flux. Finally, enzymes can moonlight as regulators of (m)RNAs, as exemplified by aconitase/IRP1 and GAPDH.
upregulating the expression of glucokinase, which promotes glucose utilization, and by increasing glycogen synthesis [5] [6] [7] . LXR activation also leads to an enhancement of triacylglycerol synthesis by upregulating the genes involved in lipogenesis [8] . Thus, the study of transcription factors such as NHRs and numerous others has contributed much to our understanding of the genetic control of metabolism [1] [2] [3] 9, 10] .
Importantly, transcriptomes only partially correlate with their corresponding proteomes, implying that RNA-based post-transcriptional regulation should play an important role in sculpting cellular proteomes [11] . Interestingly, a few metabolic enzymes had been noted to bind RNA themselves and, in some instances, participate in the post-transcriptional control of specific mRNAs [12] . For example, thymidine synthase (TYMS) can bind and inhibit the translation of its own RNA when the levels of its substrates are low, establishing a negative feedback loop [13] [14] [15] . Conceptually, such a mechanism represents a simple yet effective way to adjust to conditions when the enzyme is not required. In this review, we discuss the emerging roles of protein-RNA interactions in controlling metabolism.
Moonlighting Enzymes: Findings from RNA Interactomes
Over the past three decades, sporadic reports have shown that metabolic enzymes can moonlight as RNA-binding proteins (RBPs) and, in some instances, regulate the expression of their target mRNAs [12, 16, 17] (Table 1) . These moonlighting enzymes (see Glossary) participate in varied metabolic pathways, such as glycolysis, the tricarboxylic acid (TCA) cycle, lipid metabolism, and deoxynucleotide biosynthesis, and catalyze different reactions. In most cases, RNA binding was observed in vitro, using filter binding or electrophoretic mobility shift assays [12, 15, [18] [19] [20] . While most of the reported moonlighting metabolic enzymes still await validation in living cells and animals, the functions and modes of RNA binding of aconitase 1 (ACO1, also known as iron regulatory protein 1, IRP1), GAPDH, and TYMS have been explored by biophysical and structural approaches [21] , and investigated in cellular and animal models as described later [22] [23] [24] [25] . Insights from these examples form the basis of the 'REM (RNAenzyme-metabolite) hypothesis', which proposes the existence of regulatory links between gene expression and intermediary metabolism mediated by moonlighting RNA-binding metabolic enzymes [17] .
Recent system-wide approaches have been developed to identify a (near) complete compendium of RBPs. Initially, two parallel works used Saccharomyces cerevisiae proteome-wide protein arrays to interrogate protein binding to RNA in vitro. These studies catalogued 180 [26] and 42 proteins [27] , respectively, as putative RBPs, including many not previously known to interact with RNA. Among the dozen metabolic enzymes reliably associated with RNA in vitro, oxidoreductases and proteins involved in lipid metabolism were the most prominent classes of putative moonlighting metabolic enzymes. The peroxisomal malate dehydrogenase (MDH3) was identified in both studies as an RBP; immunoprecipitation followed by microarray (RIP-Chip) showed modest RNA-binding capacity towards a limited pool of target RNAs [26] . Because the peroxisome is not an organelle classically associated with RNA biology, these results called for further experimental validation in cellular models.
To address the technical limitations of in vitro RBP identification screens, two groups developed in parallel a new approach named RNA interactome capture (Figure 1 ). Applying UV crosslinking to proliferative cell monolayers, followed by stringent denaturing oligo(dT) isolation of protein-RNA complexes and quantitative mass spectrometry, these studies identified a total of 1106 high-confidence RBPs in HeLa and HEK293 cells [28, 29] . Notably, hundreds of them were novel RNA interactors and lacked known RNA-binding domains (RBDs). This method offers several advantages over previous approaches: (i) UV light promotes free radical formation at the nucleotide base that can establish covalent bonds only with amino acids placed at 'zero distance' (2 Å); (ii) UV crosslinking does not promote protein-protein crosslinks; (iii) because UV is applied directly to living cells, hybridization with oligo(dT) captures native protein-RNA complexes; (iv) nucleic acid hybridization is compatible with high salt and denaturing agents including chaotropic detergents, thus allowing stringent removal of noncovalent binders; and (v) to qualify as high-confidence RBP, quantitative information and rigorous statistic methods are applied [29, 30] .
Among the newly identified RBP classes, the RNA interactome studies reported 23 distinct metabolic enzymes associated with polyadenylated RNAs [28, 29, 31] (Table 1 ), suggesting that the interplay between RNA and metabolism is broader than previously realized and supporting the REM network hypothesis. Among these moonlighters, aldolase and trifunctional enzyme subunit b (HADHB) had previously been recognized to bind RNA in vitro [12] and the interaction of enolase 1 (ENO1), hydroxymethyltransferase (SHMT1), and pyruvate kinase M2 (PKM2) with RNA was validated in cells by an independent approach [29, 30] . Applying UV crosslinking, immunoprecipitation, and RNA sequencing (CLIPseq), it was shown that ENO1 and SHMT2 associate with hundreds of different mRNAs in HeLa cells, but display distinct binding patterns from each other, suggesting selectivity of binding [29] . In agreement, bacterial enolase has been recently identified, together with the RNase E, as a part of the degradosome complex, which suggests that the relationship of this enzyme with RNA is already observable in prokaryotes [32] . Although the 23 moonlighting enzymes identified by the RNA interactome studies belong to different metabolic pathways and catalyze distinct reactions, 13 of them bind either dinucleotides or mononucleotides (Table 1 ). This suggests that protein domains commonly involved in nucleotide binding, such as the Rossmann fold, may represent suitable protein surfaces to interact with RNA, as discussed in more detail later.
Interestingly, some of the already known and newly discovered moonlighting RBPs are linked to hereditary diseases. Mutations in inosine 5 0 -monophosphate dehydrogenase 1 (IMPDH1), a dual RNA-binding and dinucleotide-binding enzyme [33] , cause retinitis pigmentosa [34] , an eye disease with severe vision impairment attributable to the progressive degeneration of the photoreceptors in the retina [35] . Importantly, the disease-associated D226N IMPDH mutant exhibits metabolic activity but it is unable to bind nucleic acids [36] . IMPDH is involved in the post-transcriptional regulation of rhodopsin mRNA and this disease-associated mutation reduces its association with polysomes and thus its translation efficiency The mitochondrial enzyme 17b-hydroxysteroid dehydrogenase 10 (HSD17B10; also known as MRPP2), catalyzes the dehydrogenation of 17-hydroxysteroids in steroidogenesis. However, it was catalogued as an RBP in HEK293 cells [28] and also moonlights as a component of mitochondrial ribonuclease P, which is involved in the processing of the mitochondrial tRNAs [39] . HSD17B10 deficiency causes neurodegeneration in humans and has been associated with Alzheimer's disease. Curiously, there is no correlation between the degree of catalytic activity of the disease-associated mutant enzymes and the severity of the disease [40] , suggesting that the molecular mechanism underlying this pathology does not primarily derive from the catalytic activity of HSD17B10. Indeed, a recent study revealed that knock-down or mutation of HSD17D10 induces a defect in the processing of the heavy strand of the mitochondrial RNA [41] . In summary, abrogation of the RNA-related function of these moonlighting metabolic enzymes is associated with phenotypic consequences, supporting the importance of these protein-RNA interactions in cell biology.
The IRP1/Aconitase Paradigm
In the early 1990s, it became clear that the RBP intensively studied for its role in the regulation of cellular iron metabolism, iron regulatory protein ( [52, 53] . IRE motifs have since been found in other mRNAs, mostly encoding proteins involved in iron homeostasis and utilization, and the mechanisms by which IRPs regulate these targets have been elucidated [54] . Specifically, IRPs bind to RNAs in iron-deficient cells, and interaction with an IRE in the 5 0 UTR blocks mRNA translation, while binding to IREs in the 3 0 UTR leads to mRNA stabilization; in this way, the IRPs are crucial to maintaining appropriate intracellular iron levels (Figure 2A,B) . Both proteins are broadly expressed across tissues and single knockout mice are viable, while simultaneous knockout of both IRPs is early embryonic lethal, indicating essential but largely redundant functions. Nevertheless, the single knockout phenotypes also demonstrate specific roles for IRP1 in erythropoiesis and the cardiovascular system, while IRP2 is of particular importance in erythroblasts and the nervous system (reviewed in [54] [55] [56] [57] ). Underscoring the medical relevance of the IRP/IRE system, mutants of the IRE element of L-ferritin mRNA that lack IRP binding cause hereditary hyperferritinemia-cataract syndrome [58] .
IRP1 and IRP2 are 60% identical and both are homologous to the mitochondrial TCA cycle enzyme aconitase ACO2 that catalyzes the isomerization of citrate to isocitrate using a cubane iron sulfur cluster (4Fe-4S) as a cofactor. However, only IRP1 displays conservation of the active site, assembles an equivalent 4Fe-4S cluster, and functions as a cytosolic aconitase. RNA-binding and aconitase activity are mutually exclusive. In iron-replete conditions IRP1 ligates the 4Fe-4S cluster and functions as an enzyme, while the cluster is disassembled when iron is scarce and the IRP1 apoprotein binds IREs to its widened cleft [21] (Figure 2C,D) . In most tissues a large proportion of the IRP1 pool is in the enzymatically active holoenzyme state [59], leaving a significant reservoir for activation of RNA-binding activity in iron deficiency.
Moonlighting Central: GAPDH
A second well-characterized example of a protein with dual metabolic and RNA-binding activity is the glycolytic enzyme GAPDH, which converts glyceraldehyde-3-phosphate to D-glycerate-1,3-bisphosphate, generating NADH. In addition to this 'housekeeping' role, multiple functions in vesicular trafficking, transcription, DNA repair, telomere maintenance, and cell death have been reported, as reviewed in [60] . Of note, GAPDH is also a part of the interferon g (IFNg)-activated inhibitor of translation (GAIT) complex that controls inflammatory mRNA translation in myeloid cells [61] . The heterotetrameric GAIT complex contains the glutamyl-prolyl tRNA synthase (EPRS), NS1-associated protein 1 (NSPA1, also known as SYNCRIP or hnRNPQ), ribosomal protein L13a (L13a), and GAPDH. While NSPA1 is a canonical RBP, EPRS, L13a, and GAPDH need to abandon their regular 'tasks' in the multisynthetase complex, the ribosome and glycolysis, respectively, to form the GAIT complex upon phosphorylation of EPRS and L13a by IFNg-induced kinases [61] . EPRS is the main RNAbinding specificity determinant within the GAIT complex; however, it is unknown whether GAPDH also contributes to the interaction with target RNAs. GAPDH has also been identified as an RBP in its own right, with reported targets ranging from mRNAs, tRNA, rRNA, a ribozyme, and viral RNA (e.g., [20, [62] [63] [64] An exciting 'REM connection' between gene regulation and metabolism involving GAPDH emerged recently from the study of T cell activation [25] (Figure 3 ). When T lymphocytes are activated, they switch from oxidative phosphorylation (OXPHOS) to aerobic glycolysis. In cells relying on OXPHOS, translation of IFNg is repressed by binding of GAPDH to an ARE in the 3 0 UTR of the IFNg mRNA ( Figure 3A ). This repression is a direct effect of GAPDH as it was preventable by RNAi knockdown, or forced engagement of the enzymatic function of GAPDH by loading T cells with glyceraldehyde-3-phosphate. Following T cell activation and the switch to aerobic glycolysis, GAPDH is no longer active as an RBP bound to IFNg mRNA and becomes fully engaged in the glycolytic pathway ( Figure 3B) . Thus, the switch to aerobic glycolysis emerges as a mechanism to antagonize the repression of effector cytokine production by GAPDH, engaging the enzyme in glycolysis rather than RNA binding.
Competition between the enzyme cofactor NAD + and RNA for binding to the same domain on GAPDH could potentially be involved in the above-mentioned effects, as it has been demonstrated that the presence of NAD + or NADH interferes with RNA binding to GAPDH in vitro [20, 63, 64, 68, 69] . By contrast, the substrate glyceraldehyde-3-phosphate has not shown inhibition of RNA binding, consistent with the RNA interaction not being mediated by the C-terminal substrate-binding region but through the N-terminal Rossmann fold. Enzyme activity is abrogated by the addition of the IFNg 3 0 UTR in a sequence-dependent manner. The RNA also inhibits the assembly of GAPDH monomers into the enzymatically active tetramer ( Figure 3C ), suggesting that the enzyme binds RNA as a monomer or dimer [19] .
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Glyceraldehyde-3-phosphate NAD While NAD + or NADH interference with RNA binding could be involved in switching between its enzymatic and RNA regulatory functions, GAPDH is also known to be post-translationally modified in various ways, with links to changes in its oligomerization state and subcellular distribution, as reviewed in [60] . S-Nitrosylation by nitric oxide at the active site cysteine can trigger GAPDH translocation to the nucleus and activation of its cell death-related functions, as can ADP-ribosylation [70, 71] . Intermolecular disulfide bond formation leads to formation of cytoplasmic GAPDH amyloid-like fibrils. Oxidative stress-induced S-glutathionylation of the catalytically active cysteine allows the enzyme to participate in shifting metabolic flux from glycolysis to the pentose phosphate pathway [72, 73] . Equally, a free sulfhydryl group has been reported to be required for RNA binding [74] , and S-glutathionylation to block the RNA-binding activity of GAPDH [65] . Thus, alterations in cell state or metabolism could also affect the RNAbinding/enzymatic function of GAPDH via post-translational modifications of the protein.
Who Affects Whom and How? flux properties [75] [76] [77] . RNA could conceivably bridge between enzymes of a pathway to foster formation of a metabolon ( Figure 4C ). Interestingly, GAPDH appears to form a higher order complex with other glycolytic enzymes, which was biochemically isolated and shown to be sensitive to RNase digestion [78] . The metabolon concept was first formulated for the TCA cycle [76] and supported by recent work [79] . Similar evidence has been obtained for other pathways such as the enzymes conducting de novo purine synthesis, which form purinosomes in the cytoplasm [80] . There is much interest in engineering metabolons for superior performance in biotechnology applications, and indeed a functional metabolon for hydrogen production in live bacteria was designed based on an RNA scaffold [81] . Could RNA-augmented metabolons be a more general occurrence in nature?
Although intuition inspired by existing examples such as aconitase/IRP1 and GAPDH might suggest that an enzyme binding to RNA would control the expression of the RNA (e.g., IRP1 regulating ferritin mRNAs or GAPDH controlling IFNg mRNA translation), it is important to realize that RNA may also affect the enzyme (e.g., its activity, localization, complex formation, biogenesis, stability, etc.). How would metabolism and metabolites affect this situation? First, metabolites and RNA could affect each other's interactions with the enzyme directly, either through mutually exclusive binding to the same domain or through allosteric effects. Enzymes are often allosterically regulated by metabolites other than their own substrates and thus a given enzyme-RNA interaction might also be regulated by 'out of left field' metabolites. Interestingly, even canonical RBPs have been reported to be able to function as metabolite sensors, for example, Musashi-1, which is allosterically inhibited by unsaturated fatty acids [82] . Second, cellular metabolite levels might influence post-translational protein modifications [metabolite-driven post-translational modifications (mPTMs)]. For example, many metabolic enzymes are acetylated and protein acetylation is linked to the cellular levels of both, acetyl-CoA and NAD + [83] .
Similar considerations apply to succinyl-CoA and succinylation, malonyl-CoA and malonylation, S-adenosyl methionine and methylation, etc. Thus, metabolism could influence RNA binding to enzymes indirectly, through changes in their PTM status; this could extend the regulatory scope of a metabolite much beyond the enzyme that metabolizes it.
By contrast, RNA itself can act as an effector of the activity of an enzyme. The protein kinase R (PKR) is activated by binding of (pathogen-derived) double-stranded RNA [84] . PKR in a monomeric state is inactive; but the interaction with double-stranded RNA (viral replication intermediaries) triggers its dimerization. As a dimer, PKR is active and can phosphorylate the eukaryotic initiation factor 2/ (eIF2/), inducing the inhibition of host cell protein synthesis to prevent viral replication and spread [85] [86] [87] . Other examples of RNA-regulated proteins include RIG-I or Toll-like receptor (TLR) 3, TLR7, and TLR8 [88, 89] . While these examples are taken from the innate immune system and the regulatory RNAs are pathogen-derived, it is perfectly conceivable that host cell genomes could express 'effector RNAs' to modulate the functions of RNA-binding enzymes and other RBPs.
These possibilities still await experimental exploration for most of the moonlighting enzymes, as even their physiological RNA partners are not yet known. Nevertheless, the above-mentioned well-studied examples indicate that several, if not all, of the above scenarios deserve consideration for their physiological relevance.
Concluding Remarks and Future Perspectives
Although cytosolic aconitase has been known for almost a quarter of a century to 'moonlight' as an RBP that regulates cellular iron metabolism, it is only now becoming apparent that many metabolic enzymes display RNA-binding activity in living cells. We can currently only speculate about the physiological relevance of this widespread phenomenon, but we point to the urgency of exploring this further to better understand whether and how metabolism and gene regulation 
